Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

Histone Deacetylase Inhibitors in Cancer Therapy | Synapse

October 14, 2009

Histone Deacetylase Inhibitors in Cancer Therapy

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

HDAC inhibitors are an important emerging therapy with single-agent activity against multiple cancers, and have significant potential in combination use.

Preguntar a la IA

Me gusta

Guardar

Compartir

Preguntar a la IA

Me gusta

Guardar

Compartir

Cite This Study

Lane et al. (Wed,) studied this question.

synapsesocial.com/papers/69d985ffe6ab964fb0835e70 https://doi.org/https://doi.org/10.1200/jco.2009.22.1291

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Histone Deacetylase Inhibitors in Programmed Cell Death and Cancer Therapy2005 · 142 citations
2Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies2005 · 24 citations
3Phase 2 study of suberoylanilide hydroxamic acid (SAHA) in relapsed or refractory indolent non-Hodgkin lymphoma: A California Cancer Consortium study2007 · 9 citations
4N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)2007 · 15 citations
5Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin2007 · 98 citations